Related Experiment Videos
Risk models for familial ovarian and breast cancer
A C Antoniou1, S A Gayther, J F Stratton
1CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom. antonis.antoniou@srl.cam.ac.uk
Genetic Epidemiology
|January 21, 2000
Summary
Genetic mutations in BRCA1 and BRCA2 genes explain most hereditary ovarian cancer risk. These genes significantly increase susceptibility to both ovarian and breast cancer in affected families.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Inherited susceptibility to breast and ovarian cancer is a significant health concern.
- BRCA1 and BRCA2 mutations are known major contributors to familial risk.
- Understanding the contribution of these genes is crucial for risk assessment and management.
Purpose of the Study:
- To investigate genetic risk models for inherited breast and ovarian cancer susceptibility.
- To determine the sufficiency of BRCA1 and BRCA2 mutations in explaining familial ovarian cancer.
- To estimate age-specific cancer risks for BRCA1 mutation carriers.
Main Methods:
- Analysis of data from high-risk families and population-based ovarian cancer cases.
- Germline mutation testing for BRCA1 and BRCA2.
- Genetic modeling using the MENDEL computer program.
- Estimation of population mutation frequencies and age-specific cancer risks.
Main Results:
- BRCA1 and BRCA2 mutations were found in 50% of high-risk ovarian cancer families.
- Population frequencies estimated at 0.00128 for BRCA1 and 0.00172 for BRCA2.
- No significant evidence for a third ovarian cancer susceptibility gene was found.
- Estimated cumulative risks for BRCA1 carriers: 66% for ovarian cancer and 45% for breast cancer by age 70.
- Higher ovarian cancer penetrance suggests influence of modifying factors.
Conclusions:
- BRCA1 and BRCA2 mutations appear sufficient to explain the majority of familial ovarian cancer.
- Unexplained familial cases may relate to mutation testing sensitivity or chance occurrences.
- Significant risks for ovarian and breast cancer associated with BRCA1 mutations warrant further investigation into modifying factors.